NCT00372723

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Loyola University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.

Detailed description

This is a pilot (preliminary) study. Patients with a diagnosis of TEN will be asked to consider participating. The study intervention is a single intravenous dose of remicaide (5 mg/kg). Standard supportive care will be given. The percentage of patients alive at 30 days after treatment with remicaide will be compared to historical controls.

Conditions

• Toxic Epidermal Necrolysis

Interventions

Type	Name	Description
DRUG	Remicaide (infliximab)	a single dose infusion of 5mg/kg Remicade (Infliximab)

Timeline

• Start date: 2006-07-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2006-09-07
• Last updated: 2013-04-26